|
1
|
Chakraborty R, Wieland CN and Comfere NI:
Molecular targeted therapies in metastatic melanoma. Pharmgenomics
Pers Med. 6:49–56. 2013.PubMed/NCBI
|
|
2
|
Tas F: Metastatic behavior in melanoma:
timing, pattern, survival, and influencing factors. J Oncol.
2012:6476842012.PubMed/NCBI
|
|
3
|
Tsao H, Chin L, Garraway LA and Fisher DE:
Melanoma: from mutations to medicine. Gene Dev. 26:1131–1155. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zigler M, Kamiya T, Brantley EC, Villares
GJ and Bar-Eli M: PAR-1 and thrombin: the ties that bind the
microenvironment to melanoma metastasis. Cancer Res. 71:6561–6566.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li B, Castano AP, Hudson TE, Nowlin BT,
Lin SL, Bonventre JV, Swanson KD and Duffield JS: The
melanoma-associated transmembrane glycoprotein Gpnmb controls
trafficking of cellular debris for degradation and is essential for
tissue repair. FASEB J. 24:4767–4781. 2010. View Article : Google Scholar
|
|
6
|
Das SK, Bhutia SK, Sokhi UK, Azab B, Su
ZZ, Boukerche H, Anwar T, Moen EL, Chatterjee D, Pellecchia M,
Sarkar D and Fisher PB: Raf kinase inhibitor RKIP inhibits
MDA-9/syntenin-mediated metastasis in melanoma. Cancer Res.
72:6217–6226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fernandez LP, Milne RL, Pita G, Floristan
U, Sendagorta E, Feito M, Avilés JA, Martin-Gonzalez M, Lázaro P,
Benítez J and Ribas G: Pigmentation-related genes and their
implication in malignant melanoma susceptibility. Exp Dermatol.
18:634–642. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schiaffino MV: Signaling pathways in
melanosome biogenesis and pathology. Int J Biochem Cell Biol.
42:1094–1104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giordano F, Simoes S and Raposo G: The
ocular albinism type 1 (OA1) GPCR is ubiquitinated and its traffic
requires endosomal sorting complex responsible for transport
(ESCRT) function. Proc Natl Acad Sci USA. 108:11906–11911. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Palmisano I, Bagnato P, Palmigiano A,
Innamorati G, Rotondo G, Altimare D, Venturi C, Sviderskaya EV,
Piccirillo R, Coppola M, et al: The ocular albinism type 1 protein,
an intracellular G protein-coupled receptor, regulates melanosome
transport in pigment cells. Hum Mol Genet. 17:3487–3501. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hilger RA, Scheulen ME and Strumberg D:
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie.
25:511–518. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marshall C: Specificity of receptor
tyrosine kinase signaling: transient versus sustained extracellular
signal-regulated kinase activation. Cell. 80:179–185. 1995.
View Article : Google Scholar
|
|
14
|
Bogenrieder T and Herlyn M: The molecular
pathology of cutaneous melanoma. Cancer Biomark. 9:267–286.
2011.
|
|
15
|
Forsea A, Del Marmol V, de Vries E, Bailey
EE and Geller AC: Melanoma incidence and mortality in Europe: new
estimates, persistent disparities. Br J Dermatol. 167:1124–1130.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bhatia S, Tykodi SS and Thompson JA:
Treatment of metastatic melanoma: an overview. Oncology (Williston
Park). 23:488–496. 2009.
|
|
17
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McKenzie JA, Liu T, Goodson AG and
Grossman D: Survivin enhances motility of melanoma cells by
supporting Akt activation and alpha5 integrin upregulation. Cancer
Res. 70:7927–7937. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marino N, Marshall JC and Steeg PS:
Protein-protein interactions: a mechanism regulating the
anti-metastatic properties of Nm23-H1. Naunyn Schmiedebergs Arch
Pharmacol. 384:351–362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agell N, Bachs O, Rocamora N and
Villalonga P: Modulation of the Ras/Raf/MEK/ERK pathway by
Ca2+, and Calmodulin. Cell Signal. 14:649–654. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang F, Steelman LS, Lee JT, Shelton JG,
Navolanic PM, Blalock WL, Franklin RA and McCubrey JA: Signal
transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine
receptors to transcription factors: potential targeting for
therapeutic intervention. Leukemia. 17:1263–1293. 2003. View Article : Google Scholar
|
|
23
|
Panka DJ, Wang W, Atkins MB and Mier JW:
The Raf inhibitor BAY 43–9006 (Sorafenib) induces
caspase-independent apoptosis in melanoma cells. Cancer Res.
66:1611–1619. 2006.
|
|
24
|
Sebolt-Leopold JS: MEK inhibitors: a
therapeutic approach to targeting the Ras-MAP kinase pathway in
tumors. Curr Pharm Des. 10:1907–1914. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hingorani SR, Jacobetz MA, Robertson GP,
Herlyn M and Tuveson DA: Suppression of BRAF(V599E) in human
melanoma abrogates transformation. Cancer Res. 63:5198–5202.
2003.PubMed/NCBI
|
